We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Efficacy Study of Trichuris Suis Ova to Treat Chronic Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01948271
Recruitment Status : Terminated (lack of efficacy)
First Posted : September 23, 2013
Last Update Posted : September 15, 2016
Information provided by (Responsible Party):
Tufts Medical Center

Brief Summary:
The purpose of this research study is to better understand whether trichuris suis ova (TSO) ingested orally may be safe and effective in the treatment of psoriasis.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: Trichuris Suis Ova Phase 1

Detailed Description:
This is an open-label study to assess the safety and efficacy of 16 weeks of treatment with 7500 trichuris suis ova (TSO 7500) given every 2 weeks (a total of 8 doses) for the treatment of moderate-to-severe, chronic, plaque-type psoriasis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Pilot Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis
Study Start Date : July 2013
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: TSO 7500
Subjects in this arm will receive doses of 7500 trichuris suis ova every two weeks, starting at the baseline visit, for a total of 8 doses.
Drug: Trichuris Suis Ova
During the treatment phase, study drug will be provided in a liquid form and will be administered every 2 weeks, starting with the Baseline visit, through Week 14.
Other Name: TSO 7500

Primary Outcome Measures :
  1. Physician's area and severity index (PASI) [ Time Frame: Screening, baseline, weeks 2, 4, 6, 8, 10, 12, 14, and 16 ]
    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. PASI produces a numeric score that can range from 0 to 72 based on the body surface area of involvement and the severity of disease (induration, erythema and scale). A PASI-50 response is defined as ≥50% improvement in PASI score from baseline; PASI-75 and PASI-90 are similarly defined.

Secondary Outcome Measures :
  1. Safety and tolerability [ Time Frame: Screening, baseline, weeks 2, 4, 6, 8, 10, 12, 14, 16, 20, and 38 ]
    Evaluated via the frequency and severity of adverse events, changes in physical examinations, stool studies (ova and parasites, culture, clostridium difficile toxin, and blood), clinical laboratories (liver function tests, creatine phosphokinase, complete metabolic profile, complete blood count), and vital signs (blood pressure, pulse and temperature).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Males or females, 18-75 years old
  2. Diagnosis of stable plaque type psoriasis for at least 6 months prior to baseline
  3. Baseline moderate to severe psoriasis, defined as:

    1. Psoriasis covering a body surface area (BSA) ≥10%;
    2. Physician's global assessment (PGA) ≥3, and;
    3. PASI ≥12
  4. Must be in good health as judged by the PI, based on medical history, physical examination, and clinical laboratories
  5. In the opinion of the PI, must be a candidate for systemic therapy or phototherapy of psoriasis
  6. If a woman, before entry she must be one of the following:

    1. Postmenopausal, defined as 45 years of age with amenorrhea for at least 18 months, or >45 years of age with amenorrhea for >6 months and a serum follicle stimulating hormone (FSH) level >40 IU/mL, or surgically postmenopausal (bilateral oophorectomy)
    2. surgically sterile (have had a hysterectomy or tubal ligation or otherwise be incapable of pregnancy)
    3. If heterosexually active, practicing a highly effective method of birth control, including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (eg, condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel), or male partner sterilization for the duration of their participation in the study and for 2 months after receiving the last administration of any study agent; or
    4. Not heterosexually active
  7. Women of childbearing potential must have a negative pregnancy test (urine and serum) prior to randomization
  8. Agree to avoid prolonged exposure to natural sunlight or tanning beds or phototherapy devices for the duration of the study
  9. Agree to avoid any prohibited concomitant medications as detailed below for the duration of the study and for 4 weeks prior to baseline
  10. Negative stool culture
  11. Subject has the ability to provide informed consent
  12. Subjects who are on inhaled or ophthalmic steroids are allowed

Exclusion Criteria:

  1. Subjects with known history of intestinal parasitic infection, even if adequately treated, in the past 5 years
  2. Subject received antibiotic, antifungal or antiparasitic medication in the last 2 weeks prior to Screening and/or would potentially require this during the study treatment period
  3. Subject with history of drug or alcohol abuse within 6 months prior to screening
  4. Subject with evidence of poor compliance with medical advice and instruction including diet or medication
  5. Subject is unable or unwilling to swallow study medication suspension
  6. Subject with a significant medical condition which puts the subject at risk for study participation and/or for any reason is considered by the Investigator to be an unsuitable candidate to receive TSO or is potentially put at risk by study procedures
  7. Subjects who has participated in another clinical trial within 30 days of screening for this trial and/or any experimental treatment for this population
  8. White blood cell count ≤3,000/mm3 (≤3.0 x 109/L) or ≥14,000/mm3 (≥14 x 109/L)
  9. Platelet count ≤ 100,000/μL (≤100 x 109/L)
  10. Serum creatinine >2 x upper limit of normal (ULN)
  11. Aspartate or alanine aminotransferase >2 x ULN
  12. Total bilirubin >2 mg/dL (34 μmol/L)
  13. Hemoglobin < 9 g/dL
  14. Subjects who are currently taking or have taken in the past 30 days, for any reason, any medication that, in the opinion of the investigator, suppressed the immune response. This may include but is not limited to systemic steroids, azathioprine, cyclosporine, tacrolimus, mycophenolate mofetil, mycophenolic acid, etanercept, adalimumab, infliximab, ustekinumab, cimzia, or any other biologic agent targeted to any cell or cytokine in the immune system.
  15. Subjects who are refractory to 2 or more biological agent plaque psoriasis therapies due to lack of efficacy
  16. Subjects currently taking or who have taken in the past 2 weeks, topical steroids
  17. Subjects on a non-stable dose of vitamin D analog in the past 30 days
  18. Subjects currently taking or who have taken in the past 30 days any medications likely to improve psoriasis and thus interfere with evaluation. This may include, in addition to the medications listed above, phototherapy, methotrexate, hydroxyurea, or acitretin
  19. Subjects with a diagnosis of inflammatory bowel disease (ulcerative colitis or Crohn's disease) or of irritable bowel syndrome
  20. Subjects with HIV-1/HIV-2 antibody, hepatitis B surface antigen, hepatitis C antibody
  21. Subject received non-steroidal anti-inflammatory drugs within 2 weeks before Baseline visit for more than 3 consecutive days, except acetylsalicylic acid ≤350 mg/d which is allowed
  22. Women who are intending to become pregnant or who are breastfeeding or planning to breastfeed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01948271

Layout table for location information
United States, Massachusetts
Tufts Medical Center
Boston, Massachusetts, United States, 02111
Sponsors and Collaborators
Tufts Medical Center
Layout table for investigator information
Principal Investigator: Alice B Gottlieb, MD, PhD Tufts Medical Center, Department of Dermatology
Additional Information:
Layout table for additonal information
Responsible Party: Tufts Medical Center
ClinicalTrials.gov Identifier: NCT01948271    
Other Study ID Numbers: TSOPSO13
First Posted: September 23, 2013    Key Record Dates
Last Update Posted: September 15, 2016
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Tufts Medical Center:
Trichuris suis ova
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases